BD Korea revenue exceeds KRW 300B…record high

Recorded revenue of KRW 313.5 billion for fiscal year 2025…25% increase compared to last year

Effect of acquisition of APM business unit fully reflected…strengthened critical care and operating room solution portfolio

Restructuring of growth pillars with expanding obesity treatment·research equipment

In the first fiscal year following the spin-off of its diabetes business unit, BD (Becton, Dickinson and Company) Korea recorded revenue exceeding KRW 300 billion, rewriting its highest performance to date.

Despite selling off a business unit that generated approximately KRW 15 billion in annual revenue, the company continued its expansion, demonstrating the success of its business reorganization through numbers. Analysts believe aggressive M&A activity and the targeting of new markets directly drove this performance.

Exceeding revenue of KRW 313.5 billion…record growth gains attention

Based on an analysis of audit reports for the 43rd to 46th fiscal years, BD Korea achieved revenue of KRW 313.5 billion in the 2025 fiscal year (October 1, 2024, to September 30, 2025).

This figure represents a 25.1% increase compared to the KRW 250.6 billion recorded in the previous fiscal year (October 1, 2023, to September 30, 2024).

Profitability indicators, including operating profit and net income, also showed significant improvement during this period.

Operating profit for 2025 reached KRW 13.8 billion, an increase of approximately 41% from the KRW 9.8 billion recorded the previous year. Net income also grew by 25.4% to 10.6 billion KRW, demonstrating the company's qualitative and quantitative growth.

In particular, this growth is considered highly significant, as it was achieved after the sale of the diabetes business unit, now called Embecta Korea, in March 2024.

BD, founded in the United States in 1897, maintains a broad portfolio that spans traditional medical consumables, such as syringes, to advanced diagnostics, life science research equipment, and drug delivery devices.

The Korean subsidiary, BD Korea, has built a robust business structure encompassing not only the hospital and diagnostic markets but also the research and pharmaceutical industries, including flow cytometry, single-cell analysis, and drug delivery devices for biopharmaceuticals.

The most direct cause of the revenue jump in 2025 is attributed to aggressive M&A.

In early October 2024, BD Korea acquired the 'Advanced Patient Monitoring (APM)' business unit from Edwards Lifesciences Korea for KRW 17.6 billion.

According to the audit report, BD Korea recognized approximately KRW 9.8 billion in goodwill through this acquisition. It secured KRW 7.1 billion in inventory assets, significantly strengthening its critical care and operating room solution portfolio.

As the APM business unit's revenue in the 2025 fiscal year was fully reflected, it served as a primary driver of overall growth.

Expansion of the GLP-1 obesity treatment market and demands for devise

The strong performance of the Medication Delivery Solutions (MDS) division also contributed positively. The expansion of the GLP-1 obesity treatment market, currently a major topic in the pharmaceutical and biotech industry, is cited as a key contributor.

BD Korea's booth at COPHEX 2025

Last year, the company showcased the BD Vystra, a disposable pen device optimized for the administration of obesity treatments, and the BD Hylok, a pre-filled syringe for high-viscosity drugs, at major exhibitions such as COPHEX 2025.

As the obesity treatment market shifts toward combination products in self-injection formats, the increased adoption of BD’s drug delivery solutions, which meet global standards, has been a key driver of the rising performance.

Analysis suggests that the distribution of diagnostic equipment within the Life Sciences (BDB) division also contributed to the revenue increase.

The next-generation flow cytometer, BD FACSLyric, achieved 200 units in domestic sales as of June 2025, demonstrating an overwhelming market share in the precision immune analysis market.

Furthermore, the company solidified its leadership in the high-value equipment market by installing the 'BD FACSDiscover A8', which integrates real-time single-cell imaging technology, at major research institutions such as Yonsei University and Hallym University.

This indicates a sustained increase not only in equipment sales revenue but also in future revenue from reagents and maintenance services.

BD Korea plans to strengthen its 'End-to-End' integrated services, supporting the entire process from the early stages of biosimilar development to production, in line with the upcoming large-scale patent expirations of major biopharmaceuticals over the next decade.

An industry official stated, "BD Korea has successfully transformed its business structure toward high-growth areas like patient monitoring and obesity treatment devices following the diabetes unit spin-off," and added, "Based on its strengths in the global supply chain and strategic partnerships with domestic pharmaceutical companies, the company's growth trend is expected to persist."